Arrowhead Pharmaceuticals Corp (ARWR) Q4 Revs Beat
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $88.24 +0.88%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $43.29 million versus the consensus estimate of $41.48 million.
Fiscal Year 2019 revenue was $168.796 million, EPS was $0.69.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities
- Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
